Valsartan/hydrochlorothiazide

Drug Profile

Valsartan/hydrochlorothiazide

Alternative Names: Co-Dio; Co-Diovan; Co-Tareg; CoDiovan; Covals; Diovan HCT; KODIO EX; KODIO MD; Miten Plus; Nisisco; Provas comp; VAH631; Valsartan HCT

Latest Information Update: 07 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Class Antihypertensives; Benzothiadiazines; Branched-chain amino acids; Small molecules
  • Mechanism of Action Angiotensin receptor antagonists; Diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypertension

Most Recent Events

  • 18 Nov 2011 Generic equivalent available in Austria, Germany, Denmark, Ireland, Italy, Netherlands, Sweden & France
  • 15 Nov 2011 Generic equivalent available in the UK for heart failure, hypertension and myocardial infarction
  • 01 May 2010 Efficacy data from the VALVET trial in Hypertension presented at the 25th Annual Scientific Meeting of the American Society of Hypertension (ASH-2010) ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top